Rimegepant Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Rimegepant comprises 63 peer-reviewed publications across 15 journals, 30 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Migraine Disorders, and Psoriasis. Most recent publication: Gepants for headache prevention in children and adolescents: A multicenter chart review study., Headache, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
    Yu S, Kim BK, Guo A, et al. · Lancet Neurol · 2023
    PubMed: PMID 37210098 · NCT06992674
  2. Pharmacological interventions for acute attacks of vestibular migraine.
    Webster KE, Dor A, Galbraith K, et al. · Cochrane Database Syst Rev · 2023
    PubMed: PMID 37042545 · NCT06992674
  3. Pharmacological interventions for prophylaxis of vestibular migraine.
    Webster K, Dor A, Galbraith K, et al. · Cochrane Database Syst Rev · 2023
    PubMed: PMID 37073858 · NCT06992674
  4. A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study.
    Sharon JD, Krauter R, Chae R, et al. · Headache · 2024
    PubMed: PMID 39344988 · NCT06748664
  5. Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Electrophysiological Study.
    Sebastianelli G, Casillo F, Di Renzo A, et al. · Toxins (Basel) · 2023
    PubMed: PMID 36668895 · NCT05888766 · Migraine Disorders
  6. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB, Croop R, Stock EG, et al. · N Engl J Med · 2019
    PubMed: PMID 31291516 · NCT05888766 · Migraine Disorders
  7. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R, Goadsby PJ, Stock DA, et al. · Lancet · 2019
    PubMed: PMID 31311674 · NCT06992674
  8. Migraine: disease characterisation, biomarkers, and precision medicine.
    Ashina M, Terwindt GM, Al-Karagholi MA, et al. · Lancet · 2021
    PubMed: PMID 33773610 · NCT05888766 · Migraine Disorders

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT03235479Migraine DisordersPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
2 hours post-dose
Placebo27.7 percentage of participants
Rimegepant 75 mg36.6 percentage of participants
NCT03235479Migraine DisordersPercentage of Participants With Freedom From Pain at 2 Hours Post-dose
2 hours post-dose
Placebo14.2 percentage of participants
Rimegepant 75 mg19.2 percentage of participants
NCT03237845Migraine DisordersPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
2 Hours
Placebo25.2 Percentage of Participants
Rimegepant 75 mg37.6 Percentage of Participants
NCT03237845Migraine DisordersPercentage of Participants With Freedom From Pain at 2 Hours Post-dose
2 Hours post-dose
Placebo12.0 Percentage of participants
Rimegepant 75 mg19.6 Percentage of participants
NCT03266588Migraine DisordersNumber of Participants With Clinically Significant Laboratory Abnormalities During the Treatment Period
PRN (2-8) and PRN (9-14) groups: Up to 52 weeks: Scheduled EOD + PRN group: Up to 12 weeks
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group4 Participants
PRN (2-8) Group3 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group1 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group3 Participants
PRN (2-8) Group1 Participants
PRN (2-8) Group2 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group10 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group4 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group2 Participants
PRN (2-8) Group31 Participants
PRN (2-8) Group10 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group1 Participants
PRN (2-8) Group1 Participants
PRN (2-8) Group1 Participants
PRN (2-8) Group16 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (2-8) Group0 Participants
PRN (9-14) Group1 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group15 Participants
PRN (9-14) Group2 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group1 Participants
PRN (9-14) Group2 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group2 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group10 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group1 Participants
PRN (9-14) Group1 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group1 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group2 Participants
PRN (9-14) Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group3 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group1 Participants
Scheduled EOD + PRN Group2 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group1 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group3 Participants
NCT03266588Migraine DisordersNumber of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period
PRN (2-8) and PRN (9-14) groups: Up to 52 weeks; Scheduled EOD + PRN group: Up to 12 weeks
PRN (2-8) Group72 Participants
PRN (2-8) Group108 Participants
PRN (2-8) Group51 Participants
PRN (2-8) Group664 Participants
PRN (2-8) Group24 Participants
PRN (2-8) Group28 Participants
PRN (2-8) Group1 Participants
PRN (2-8) Group30 Participants
PRN (2-8) Group26 Participants
PRN (2-8) Group57 Participants
PRN (2-8) Group19 Participants
PRN (2-8) Group53 Participants
PRN (2-8) Group1 Participants
PRN (2-8) Group56 Participants
PRN (9-14) Group16 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group0 Participants
PRN (9-14) Group17 Participants
PRN (9-14) Group28 Participants
PRN (9-14) Group315 Participants
PRN (9-14) Group13 Participants
PRN (9-14) Group19 Participants
PRN (9-14) Group21 Participants
PRN (9-14) Group41 Participants
PRN (9-14) Group9 Participants
PRN (9-14) Group38 Participants
PRN (9-14) Group16 Participants
PRN (9-14) Group28 Participants
Scheduled EOD + PRN Group109 Participants
Scheduled EOD + PRN Group8 Participants
Scheduled EOD + PRN Group7 Participants
Scheduled EOD + PRN Group9 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group4 Participants
Scheduled EOD + PRN Group2 Participants
Scheduled EOD + PRN Group7 Participants
Scheduled EOD + PRN Group8 Participants
Scheduled EOD + PRN Group5 Participants
Scheduled EOD + PRN Group2 Participants
Scheduled EOD + PRN Group12 Participants
Scheduled EOD + PRN Group0 Participants
Scheduled EOD + PRN Group3 Participants
NCT03461757Migraine DisordersPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
2 hours post-dose
Placebo26.8 percentage of participants
Rimegepant 75 mg ODT35.1 percentage of participants
NCT03461757Migraine DisordersPercentage of Participants With Freedom From Pain at 2 Hours Post-dose
2 hours post-dose
Placebo10.9 percentage of participants
Rimegepant 75 mg ODT21.2 percentage of participants
NCT03732638Migraine DisordersChange From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase
OP and Weeks 9 to 12 of the DBT phase
Placebo - Randomization Phase-3.5 Total Migraine Days per Month
Rimegepant - Randomization Phase-4.3 Total Migraine Days per Month
NCT04574362Migraine DisordersPercentage of Participants Who Had Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose
2 hours post-dose
Placebo35.8 Percentage of participants
Rimegepant 75 mg50.5 Percentage of participants
NCT04574362Migraine DisordersPercentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose
2 hours post-dose
Placebo10.7 Percentage of participants
Rimegepant 75 mg19.8 Percentage of participants
NCT05248997—Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose
Baseline, 2 hours post-dose
Placebo-2.61 Scores on a scale
Rimegepant 75 mg-2.70 Scores on a scale
NCT05262517Temporomandibular Joint DisordersSPID From Baseline to 24-Hours Post-dose (SPID-24)
Baseline (0 hours) to 24-hours post-dose
Placebo-109.79 Unit on a scale
Rimegepant (BHV3000)-104.66 Unit on a scale
NCT05262517Temporomandibular Joint DisordersSum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose (SPID-2)
Baseline (0 hours) to 2-hours post-dose
Placebo-3.67 Units on a scale
Rimegepant (BHV3000)-3.82 Units on a scale
NCT05371652Migraine DisordersFollow-up Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation
From Week 52 to Week 54 of the follow-up safety period
Rimegepant 75 mg ODT0 Participants
NCT05371652Migraine DisordersFollow-up Safety Period: Number of Participants With Chemistry Test Abnormalities
From Week 52 to Week 54 of the follow-up safety period
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
NCT05371652Migraine DisordersFollow-up Safety Period: Number of Participants With ECG Abnormalities
From Week 52 to Week 54 of the follow-up safety period
Rimegepant 75 mg ODT209 Participants
Rimegepant 75 mg ODT2 Participants
Rimegepant 75 mg ODT2 Participants
Rimegepant 75 mg ODT0 Participants
NCT05371652Migraine DisordersFollow-up Safety Period: Number of Participants With Hematology Test Abnormalities
From Week 52 to Week 54 of the follow-up safety period
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
NCT05371652Migraine DisordersFollow-up Safety Period: Number of Participants With SAEs
From Week 52 to Week 54 of the follow-up safety period
Rimegepant 75 mg ODT0 Participants
NCT05371652Migraine DisordersFollow-up Safety Period: Number of Participants With TEAEs
From Week 52 to Week 54 of the follow-up safety period
Rimegepant 75 mg ODT24 Participants
NCT05371652Migraine DisordersFollow-up Safety Period: Number of Participants With Vital Signs Abnormalities.
From Week 52 to Week 54 of the follow-up safety period
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT5 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT1 Participants
NCT05371652Migraine DisordersTreatment Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation
From Day 1 of study treatment up to Week 52 of the treatment safety period
Rimegepant 75 mg ODT1 Participants
NCT05371652Migraine DisordersTreatment Safety Period: Number of Participants With Chemistry Test Abnormalities
From Day 1 of study treatment up to Week 52 of the treatment safety period
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT4 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT2 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
NCT05371652Migraine DisordersTreatment Safety Period: Number of Participants With Electrocardiogram (ECG) Abnormalities
From Day 1 of study treatment up to Week 52 of the treatment safety period
Rimegepant 75 mg ODT6 Participants
Rimegepant 75 mg ODT225 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
NCT05371652Migraine DisordersTreatment Safety Period: Number of Participants With Hematology Test Abnormalities
From Day 1 of study treatment up to Week 52 of the treatment safety period
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT1 Participants
NCT05371652Migraine DisordersTreatment Safety Period: Number of Participants With Serious Adverse Events (SAEs)
From Day 1 of study treatment up to Week 52 of the treatment safety period
Rimegepant 75 mg ODT7 Participants
NCT05371652Migraine DisordersTreatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
From Day 1 of study treatment up to Week 52 of the treatment safety period
Rimegepant 75 mg ODT203 Participants
NCT05371652Migraine DisordersTreatment Safety Period: Number of Participants With Vital Signs Abnormalities
From Day 1 of study treatment up to Week 52 of the treatment safety period
Rimegepant 75 mg ODT1 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT0 Participants
Rimegepant 75 mg ODT12 Participants
Rimegepant 75 mg ODT17 Participants
Rimegepant 75 mg ODT9 Participants
NCT05399459Migraine DisordersPercentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose
2 hours post-dose
Placebo13.0 Percentage of participants
Rimegepant 25 mg21.0 Percentage of participants
Rimegepant 75 mg32.4 Percentage of participants
NCT05399485Migraine DisordersMean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase
Baseline, Week 9 to Week 12 of the DBT phase
Placebo-1.4 Days/month
Rimegepant-2.4 Days/month

Publications by year

1972–2026: 63 publications.

1972
1
1990
1
2001
1
2002
1
2007
1
2011
1
2014
3
2016
2
2017
3
2018
2
2019
5
2020
1
2021
3
2022
6
2023
7
2024
10
2025
8
2026
7

Publications by indication

Migraine Disorders (38)

  • Gepants for headache prevention in children and adolescents: A multicenter chart review study.
    Headache · 2026 · PMID 41235617 · NCT05156398
  • Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings.
    Pain Manag · 2026 · PMID 42047365 · NCT05518123
  • A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.
    Headache · 2026 · PMID 40583813 · NCT03732638
  • Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials.
    Headache · 2026 · PMID 41652666 · NCT03461757
  • Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study.
    Pain Manag · 2026 · PMID 41930741 · NCT05509400

Psoriasis (15)

Publications by journal

Trial-results highlights

In studies evaluating Rimegepant for migraine disorders, participants reported freedom from their most bothersome symptom (MBS) at 2 hours post-dose. In NCT03235479, 36.6% of participants in the Rimegepant 75 mg arm achieved freedom from MBS, compared to 27.7% in the placebo arm. Similarly, in NCT03237845, 37.6% of participants in the Rimegepant 75 mg arm reported freedom from MBS, while 25.2% in the placebo arm did. In another study, NCT03461757, 35.1% of participants in the Rimegepant 75 mg ODT arm achieved freedom from MBS at 2 hours post-dose, compared to 26.8% in the placebo arm.

Freedom from pain at 2 hours post-dose was also assessed. In NCT03235479, 19.2% of participants in the Rimegepant 75 mg arm achieved freedom from pain, compared to 14.2% in the placebo arm. For NCT03237845, 19.6% of participants in the Rimegepant 75 mg arm reported freedom from pain, while 12.0% in the placebo arm did. In NCT03461757, 21.2% of participants in the Rimegepant 75 mg ODT arm achieved freedom from pain at 2 hours post-dose, compared to 10.9% in the placebo arm.

Safety outcomes were reported in NCT03266588 for the PRN (2-8) Group. The number of participants with clinically significant laboratory abnormalities during the treatment period included counts of:

  • 0 participants
  • 0 participants
  • 4 participants
  • 3 participants
  • 0 participants
  • 1 participant
The number of participants with serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation during the treatment period included counts of:
  • 72 participants
  • 108 participants
  • 51 participants
  • 664 participants
  • 24 participants
  • 28 participants
All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Rimegepant publications (63)

2026 (7 papers)

  1. Gepants for headache prevention in children and adolescents: A multicenter chart review study.
    Shin L, Mentz O, Gelfand AA, et al. · Headache · 2026 · Derived
    PubMed: PMID 41235617 · NCT05156398 · Migraine Disorders
  2. Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings.
    Pozo-Rosich P, Gien López JA, Lisewski P, et al. · Pain Manag · 2026 · Derived
    PubMed: PMID 42047365 · NCT05518123 · Migraine Disorders
  3. A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.
    Kudrow D, Croop RS, Thiry A, et al. · Headache · 2026 · Derived
    PubMed: PMID 40583813 · NCT03732638 · Migraine Disorders
  4. Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial.
    Franjic D, Fountaine RJ, Nalpas C, et al. · PLoS One · 2026 · Derived
    PubMed: PMID 41779821 · NCT05248997
  5. Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials.
    Charleston L, Armand CE, Monteith TS, et al. · Headache · 2026 · Derived
    PubMed: PMID 41652666 · NCT03461757 · Migraine Disorders
  6. Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study.
    Ashina M, McAllister P, Gaul C, et al. · Pain Manag · 2026 · Derived
    PubMed: PMID 41930741 · NCT05509400 · Migraine Disorders
  7. A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.
    Antinew J, Fountaine RJ, Loprinzo V, et al. · J Headache Pain · 2026 · Derived
    PubMed: PMID 41366286 · NCT05207865 · Migraine Disorders

2025 (8 papers)

  1. Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China.
    Zhang M, Guo A, Wu J, et al. · Cephalalgia · 2025 · Derived
    PubMed: PMID 41066271 · NCT05371652 · Migraine Disorders
  2. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.
    Pozo-Rosich P, López JAG, Lisewski P, et al. · Cephalalgia · 2025 · Derived
    PubMed: PMID 41255098 · NCT05518123 · Migraine Disorders
  3. Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study.
    Kudrow D, Hutchinson S, Pixton GC, et al. · Pain Ther · 2025 · Derived
    PubMed: PMID 39520634 · NCT03266588 · Migraine Disorders
  4. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
    Kitamura S, Matsumori Y, Yamamoto T, et al. · Headache · 2025 · Derived
    PubMed: PMID 40542538 · NCT05399485 · Migraine Disorders
  5. Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial.
    Ikeda K, Matsumori Y, Kudo M, et al. · Headache · 2025 · Derived
    PubMed: PMID 40586377 · NCT05399459 · Migraine Disorders
  6. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study).
    Iannone LF, Vaghi G, Sebastianelli G, et al. · J Headache Pain · 2025 · Derived
    PubMed: PMID 39762740 · NCT05903027 (GAINER) · Migraine Disorders
  7. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.
    Ashina M, McAllister P, Gaul C, et al. · Cephalalgia · 2025 · Derived
    PubMed: PMID 41255093 · NCT05509400 · Migraine Disorders
  8. Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study.
    Ailani J, Pavlovic J, Pixton GC, et al. · Cephalalgia · 2025 · Derived
    PubMed: PMID 40629887 · NCT03266588 · Migraine Disorders

2024 (10 papers)

  1. A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study.
    Sharon JD, Krauter R, Chae R, et al. · Headache · 2024 · Trial result
    PubMed: PMID 39344988 · NCT06748664
  2. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
    Yu S, Guo A, Wang Z, et al. · J Headache Pain · 2024 · Derived
    PubMed: PMID 38627638 · NCT04574362 · Migraine Disorders
  3. First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.
    Yang Z, Wang X, Niu M, et al. · J Headache Pain · 2024 · Derived
    PubMed: PMID 39333875 · NCT05709106 · Migraine Disorders
  4. Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study.
    True D, Mullin K, Croop R, et al. · Pain Ther · 2024 · Derived
    PubMed: PMID 38985436 · NCT03266588 · Migraine Disorders
  5. Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison.
    Mahon R, Tiwari S, Koch M, et al. · J Comp Eff Res · 2024 · Derived
    PubMed: PMID 38174577 · NCT03732638 · Migraine Disorders
  6. Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lipton RB, Thiry A, Morris BA, et al. · J Pain Res · 2024 · Derived
    PubMed: PMID 39070853 · NCT03235479 · Migraine Disorders
  7. Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics.
    Fullerton T, Pixton G · J Pain Res · 2024 · Derived
    PubMed: PMID 38764606 · NCT03266588 · Migraine Disorders
  8. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
    Croop R, Berman G, Kudrow D, et al. · Cephalalgia · 2024 · Derived
    PubMed: PMID 38659334 · NCT03266588 · Migraine Disorders
  9. Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
    Schwedt TJ, Myers Oakes TM, Martinez JM, et al. · Neurol Ther · 2024 · Background
    PubMed: PMID 37948006 · NCT05127486 (CHALLENGE-MIG) · Migraine Disorders
  10. Update on psoriasis: A review.
    Rajguru JP, Maya D, Kumar D, et al. · J Family Med Prim Care · 2024 · Background
    PubMed: PMID 32110559 · NCT04629950 · Psoriasis

2023 (7 papers)

  1. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
    Yu S, Kim BK, Guo A, et al. · Lancet Neurol · 2023 · Trial result
    PubMed: PMID 37210098 · NCT06992674
  2. Pharmacological interventions for acute attacks of vestibular migraine.
    Webster KE, Dor A, Galbraith K, et al. · Cochrane Database Syst Rev · 2023 · Trial result
    PubMed: PMID 37042545 · NCT06992674
  3. Pharmacological interventions for prophylaxis of vestibular migraine.
    Webster K, Dor A, Galbraith K, et al. · Cochrane Database Syst Rev · 2023 · Trial result
    PubMed: PMID 37073858 · NCT06992674
  4. Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Electrophysiological Study.
    Sebastianelli G, Casillo F, Di Renzo A, et al. · Toxins (Basel) · 2023 · Trial result
    PubMed: PMID 36668895 · NCT05888766 · Migraine Disorders
  5. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
    Russo CV, Saccà F, Braca S, et al. · Cephalalgia · 2023 · Trial result
    PubMed: PMID 36946234 · NCT06748664
  6. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305).
    Powell LC, L'Italien G, Popoff E, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 36417057 · NCT03732638 · Migraine Disorders
  7. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
    Lipton RB, Blumenfeld A, Jensen CM, et al. · Cephalalgia · 2023 · Derived
    PubMed: PMID 36739511 · NCT03237845 · Migraine Disorders

2022 (6 papers)

  1. CGRP measurements in human plasma - a methodological study.
    Messlinger K, Vogler B, Kuhn A, et al. · Cephalalgia · 2022 · Trial result
    PubMed: PMID 34266288 · NCT05888766 · Migraine Disorders
  2. The monoclonal CGRP-receptor blocking antibody erenumab has different effects on brainstem and cortical sensory-evoked responses.
    Casillo F, Sebastianelli G, Di Renzo A, et al. · Cephalalgia · 2022 · Trial result
    PubMed: PMID 35637558 · NCT05888766 · Migraine Disorders
  3. Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
    Alpuente A, Gallardo VJ, Asskour L, et al. · Cephalalgia · 2022 · Trial result
    PubMed: PMID 34601944 · NCT05888766 · Migraine Disorders
  4. Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine.
    Alpuente A, Gallardo VJ, Asskour L, et al. · Ann Neurol · 2022 · Trial result
    PubMed: PMID 36054144 · NCT05888766 · Migraine Disorders
  5. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
    Johnston KM, Powell L, Popoff E, et al. · Clin J Pain · 2022 · Derived
    PubMed: PMID 36125279 · NCT03461757 · Migraine Disorders
  6. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).
    Johnston K, Harris L, Powell L, et al. · J Headache Pain · 2022 · Derived
    PubMed: PMID 35038983 · NCT03266588 · Migraine Disorders

2021 (3 papers)

  1. Migraine: disease characterisation, biomarkers, and precision medicine.
    Ashina M, Terwindt GM, Al-Karagholi MA, et al. · Lancet · 2021 · Trial result
    PubMed: PMID 33773610 · NCT05888766 · Migraine Disorders
  2. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.
    Johnston KM, L'Italien G, Popoff E, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 34455556 · NCT03266588 · Migraine Disorders
  3. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
    Croop R, Lipton RB, Kudrow D, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33338437 · NCT03732638 · Migraine Disorders

2020 (1 paper)

  1. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K, Kudrow D, Croop R, et al. · Neurology · 2020 · Derived
    PubMed: PMID 31932515 · NCT03266588 · Migraine Disorders

2019 (5 papers)

  1. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB, Croop R, Stock EG, et al. · N Engl J Med · 2019 · Trial result
    PubMed: PMID 31291516 · NCT05888766 · Migraine Disorders
  2. The Epidemiology of Vestibular Migraine: A Population-based Survey Study.
    Formeister EJ, Rizk HG, Kohn MA, et al. · Otol Neurotol · 2019 · Trial result
    PubMed: PMID 30020261 · NCT06748664
  3. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R, Goadsby PJ, Stock DA, et al. · Lancet · 2019 · Trial result
    PubMed: PMID 31311674 · NCT06992674
  4. Review of safety and efficacy of approved systemic psoriasis therapies.
    Kaushik SB, Lebwohl MG · Int J Dermatol · 2019 · Background
    PubMed: PMID 30246393 · NCT04629950 · Psoriasis
  5. Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxinA.
    Aschenbeck KA, Hordinsky MK, Kennedy WR, et al. · J Am Acad Dermatol · 2019 · Background
    PubMed: PMID 30420008 · NCT04629950 · Psoriasis

2018 (2 papers)

  1. Phototherapy of Psoriasis, a Chronic Inflammatory Skin Disease.
    Rácz E, Prens EP · Adv Exp Med Biol · 2018 · Background
    PubMed: PMID 29124709 · NCT04629950 · Psoriasis
  2. Psoriasis.
    Greb JE, Goldminz AM, Elder JT, et al. · Nat Rev Dis Primers · 2018 · Background
    PubMed: PMID 27883001 · NCT04629950 · Psoriasis

2017 (3 papers)

  1. Vestibular migraine in multicenter neurology clinics according to the appendix criteria in the third beta edition of the International Classification of Headache Disorders.
    Cho SJ, Kim BK, Kim BS, et al. · Cephalalgia · 2017 · Trial result
    PubMed: PMID 26224714 · NCT06748664
  2. The Role of the Nervous System in the Pathophysiology of Psoriasis: A Review of Cases of Psoriasis Remission or Improvement Following Denervation Injury.
    Zhu TH, Nakamura M, Farahnik B, et al. · Am J Clin Dermatol · 2017 · Background
    PubMed: PMID 26935938 · NCT04629950 · Psoriasis
  3. Psoriasis and comorbid diseases: Implications for management.
    Takeshita J, Grewal S, Langan SM, et al. · J Am Acad Dermatol · 2017 · Background
    PubMed: PMID 28212760 · NCT04629950 · Psoriasis

2016 (2 papers)

  1. Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity.
    Kashem SW, Riedl MS, Yao C, et al. · Immunity · 2016 · Background
    PubMed: PMID 26377898 · NCT04629950 · Psoriasis
  2. Calcitonin Gene-Related Peptide-Exposed Endothelial Cells Bias Antigen Presentation to CD4+ T Cells toward a Th17 Response.
    Ding W, Stohl LL, Xu L, et al. · J Immunol · 2016 · Background
    PubMed: PMID 26829986 · NCT04629950 · Psoriasis

2014 (3 papers)

  1. Habituation and sensitization in primary headaches.
    Coppola G, Di Lorenzo C, Schoenen J, et al. · J Headache Pain · 2014 · Trial result
    PubMed: PMID 23899115 · NCT05888766 · Migraine Disorders
  2. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
    Marcus R, Goadsby PJ, Dodick D, et al. · Cephalalgia · 2014 · Derived
    PubMed: PMID 23965396 · NCT01430442 · Migraine Disorders
  3. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation.
    Riol-Blanco L, Ordovas-Montanes J, Perro M, et al. · Nature · 2014 · Background
    PubMed: PMID 24759321 · NCT04629950 · Psoriasis

2011 (1 paper)

  1. Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner.
    Ostrowski SM, Belkadi A, Loyd CM, et al. · J Invest Dermatol · 2011 · Background
    PubMed: PMID 21471984 · NCT04629950 · Psoriasis

2007 (1 paper)

  1. Plasma concentration of selected neuropeptides in patients suffering from psoriasis.
    Reich A, Orda A, Wiśnicka B, et al. · Exp Dermatol · 2007 · Background
    PubMed: PMID 17437485 · NCT04629950 · Psoriasis

2002 (1 paper)

  1. Calcitonin gene-related peptide in Langerhans cells in psoriatic plaque lesions.
    He Y, Ding G, Wang X, et al. · Chin Med J (Engl) · 2002 · Background
    PubMed: PMID 11776062 · NCT04629950 · Psoriasis

2001 (1 paper)

  1. The interrelations of migraine, vertigo, and migrainous vertigo.
    Neuhauser H, Leopold M, von Brevern M, et al. · Neurology · 2001 · Trial result
    PubMed: PMID 11222783 · NCT06748664

1990 (1 paper)

  1. The role of cutaneous sensory nerves in the maintenance of psoriasis.
    Farber EM, Lanigan SW, Boer J, et al. · Int J Dermatol · 1990 · Background
    PubMed: PMID 2397964 · NCT04629950 · Psoriasis

1972 (1 paper)

  1. Remission of psoriasis vulgaris from the use of nerve-blocking agents.
    Perlman HH · Arch Dermatol · 1972 · Background
    PubMed: PMID 5009614 · NCT04629950 · Psoriasis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).